Man Group
AVTX icon

Man Group’s Avalo Therapeutics AVTX Stock Holding History

Man Group’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$695K Buy
+46,553
New +$728K ﹤0.01% 1963

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Man Group's AVTX Position: Q1 2026 in Review

Man Group opened a new position in Avalo Therapeutics (AVTX) in Q1 2026: 46,553 shares worth $695K. The stake represents ﹤0.01% of the portfolio and ranks #1963 among its holdings.

97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Man Group held 46,553 shares of Avalo Therapeutics worth $695K as of Q1 2026.
  • Avalo Therapeutics was a new Man Group position in Q1 2026.
  • Avalo Therapeutics made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #1963 holding.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.